Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Cytokinetics Inc (NASDAQ: CYTK) closed at $64.6 in the last session, up 2.01% from day before closing price of $63.33. In other words, the price has increased by $2.01 from its previous closing price. On the day, 1.61 million shares were traded. CYTK stock price reached its highest trading level at $65.08 during the session, while it also had its lowest trading level at $62.17.
Ratios:
We take a closer look at CYTK’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.88 and its Current Ratio is at 6.88.
On April 24, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $55.Barclays initiated its Overweight rating on April 24, 2025, with a $55 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 05 ’26 when Callos Andrew sold 15,000 shares for $60.28 per share. The transaction valued at 904,200 led to the insider holds 50,440 shares of the business.
Callos Andrew sold 1,798 shares of CYTK for $112,585 on Jan 02 ’26. The EVP, Chief Commercial Officer now owns 50,440 shares after completing the transaction at $62.62 per share. On Jan 02 ’26, another insider, ANDREW CALLOS, who serves as the Officer of the company, bought 59,570 shares for $63.54 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 7898314240 and an Enterprise Value of 8286032384. For the stock, the TTM Price-to-Sale (P/S) ratio is 90.57. Its current Enterprise Value per Revenue stands at 95.011 whereas that against EBITDA is -14.71.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.54, which has changed by 0.34773362 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $70.98, while it has fallen to a 52-week low of $29.31. The 50-Day Moving Average of the stock is 1.46%, while the 200-Day Moving Average is calculated to be 37.65%.
Shares Statistics:
According to the various share statistics, CYTK traded on average about 1.96M shares per day over the past 3-months and 2099920 shares per day over the past 10 days. A total of 122.12M shares are outstanding, with a floating share count of 119.88M. Insiders hold about 1.95% of the company’s shares, while institutions hold 115.55% stake in the company. Shares short for CYTK as of 1767139200 were 13837421 with a Short Ratio of 7.07, compared to 1764288000 on 12948508. Therefore, it implies a Short% of Shares Outstanding of 13837421 and a Short% of Float of 14.66.
Earnings Estimates
. The current rating of Cytokinetics Inc (CYTK) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.55, with high estimates of -$1.34 and low estimates of -$1.79.
Analysts are recommending an EPS of between -$4.95 and -$6.81 for the fiscal current year, implying an average EPS of -$6.07. EPS for the following year is -$5.87, with 7.0 analysts recommending between -$4.62 and -$7.21.
Revenue Estimates
For the next quarter, 16 analysts are estimating revenue of $15.13M. There is a high estimate of $68M for the next quarter, whereas the lowest estimate is $4.8M.
A total of 19 analysts have provided revenue estimates for CYTK’s current fiscal year. The highest revenue estimate was $153.83M, while the lowest revenue estimate was $70.28M, resulting in an average revenue estimate of $80.63M. In the same quarter a year ago, actual revenue was $18.47MBased on 18 analysts’ estimates, the company’s revenue will be $141.19M in the next fiscal year. The high estimate is $371.2M and the low estimate is $54.1M.
